Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Bioactive glass could ease ear surgery After-Effects

NCT ID NCT07496112

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using bioactive glass granules during a second ear surgery can improve quality of life for people with ongoing problems like discharge, dizziness, or trouble using hearing aids. Fifty adults who had prior ear surgery will receive the procedure and be followed for changes in symptoms and daily function. The goal is to see if this material makes the ear cavity more stable and reduces complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
S53P4 bioactive glass granules
What this could lead to
If successful, this could offer a safe way to improve daily life for people with chronic ear cavity problems after surgery.
What could go wrong
This is a small, early-stage study with only 50 participants. The procedure is surgical and carries risks like infection or failure to improve symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult patients requiring rehabilitation of radical open cavity after a previous canal wall down tympanoplasty. The trial will include at least 50 consecutives patients whom it is planned rehabilitation of radical cavity and mastoid obliteration with S53P4 Bonalive granules. Patients with a history of canal wall down (CWD) tympanoplasty who present with persistent symptoms such as discharge, vertigo, impaired water activities or difficulty with hearing aids will be included.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * underwent a canal wall down tympanoplasty or a previous obliteration attempt more than a year ago * present with symptoms related to unstable cavity such as discharge, vertigo, impaired water activities or difficulty with hearing aids will be included * patients Over 18 years who signed informed consent Exclusion Criteria: * Active cholesteatoma * Earlier radiation of Head and Neck area * Pregnancy * Important systemic comorbidities

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic cholesteatomatous otitis media are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Trial Office

    Legnano, Italy, 20025, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.